(Total Views: 2078)
Posted On: 07/11/2021 2:29:13 PM
Post# of 148870
2012 cytodyn buys pro140, Nader is ceo at that time.
2013 Tony c is named chairman of board
2017 Tony named executive chairman, effectivly replacing Nader. Nader is still ceo but Tony is in charge of planning, business dev. And operations.
2018 cytodyn agrees to buy prostegene, Pestell is on bod now
In nov 2018, the tnbc trial is set to start, 1sr patient enrolled in august, after Pestell is fired in July. In august Pestell sues cytodyn. In July 2018 cytodyn has meeting with fda over prostagene. I think it is interesting that cytodyn found out what the status of prostagene’s diagnostic was in June, fired Pestell in July and got the cancer trial started in august. It seems obvious that Pestell was not starting the cancer trial until the prostagene deal went through.
It was April of 2018 that Tony was replaced by Scott Kelly as cob, Tony sues cytodyn as a result.
April 2020 the original BLA for combo was filed
May of 2020 is when the fda had some problem with it
July 2020 is when we got the RTF.
Incell dx was brought on in July of 2019, Bruce Patterson was still on board with cytodyn on July of 2020.
I don’t know how this 13d group internally looked past this sequence of events relating to their own members and thinks they have any chance of replacing the Nader mgmnt team and bod. Tony, Pestell and Bruce are all in it for the money. The first think the 13d group wants to do is buy incell, at our expense to enriches Bruce and his investors. Just like what Tony did for Pestell. Nader has tried to navigate these expensive distractions by focusing on getting leronlimab through trials, raising money to pay for it and getting distribution deals. This is as plain as I can make it, don’t listen to this groups attempt to make everything a Nader problem, it is their doing from all the way back in 2017 when Tony, an ex gilead BP got involved.
2013 Tony c is named chairman of board
2017 Tony named executive chairman, effectivly replacing Nader. Nader is still ceo but Tony is in charge of planning, business dev. And operations.
2018 cytodyn agrees to buy prostegene, Pestell is on bod now
In nov 2018, the tnbc trial is set to start, 1sr patient enrolled in august, after Pestell is fired in July. In august Pestell sues cytodyn. In July 2018 cytodyn has meeting with fda over prostagene. I think it is interesting that cytodyn found out what the status of prostagene’s diagnostic was in June, fired Pestell in July and got the cancer trial started in august. It seems obvious that Pestell was not starting the cancer trial until the prostagene deal went through.
It was April of 2018 that Tony was replaced by Scott Kelly as cob, Tony sues cytodyn as a result.
April 2020 the original BLA for combo was filed
May of 2020 is when the fda had some problem with it
July 2020 is when we got the RTF.
Incell dx was brought on in July of 2019, Bruce Patterson was still on board with cytodyn on July of 2020.
I don’t know how this 13d group internally looked past this sequence of events relating to their own members and thinks they have any chance of replacing the Nader mgmnt team and bod. Tony, Pestell and Bruce are all in it for the money. The first think the 13d group wants to do is buy incell, at our expense to enriches Bruce and his investors. Just like what Tony did for Pestell. Nader has tried to navigate these expensive distractions by focusing on getting leronlimab through trials, raising money to pay for it and getting distribution deals. This is as plain as I can make it, don’t listen to this groups attempt to make everything a Nader problem, it is their doing from all the way back in 2017 when Tony, an ex gilead BP got involved.
(21)
(1)Scroll down for more posts ▼
